-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3825 “I Really Wish We Had a Talk on Advocacy That Wasn't Boring”: Toward a Health Advocacy Curriculum That Meets the Needs of Canadian Hematology Residents

Program: Oral and Poster Abstracts
Session: 909. Education, Communication, and Workforce: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, Education, Real-world evidence
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Mitali Chaudhary, MD1*, Martina Trinkaus2*, Eric Tseng3*, Francine Schneider, PhD4* and Michael Douglas Scott, MD2

1St. Michael's Hospital, General Internal Medicine, University of Toronto, Toronto, ON, Canada
2Division of Hematology-Oncology, St. Michael's Hospital, Unity Health Toronto, Toronto, Canada
3Division of Hematology-Oncology, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada
4Department of Health Promotion/Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands

Background: There is an ongoing need to incorporate health advocacy training into postgraduate medical education. In Canadian hematology training, there are no existing dedicated health advocacy curricula. As a first step toward the development of such curricula, we sought to determine what the health advocate role entails for hematologists, identify necessary health advocacy competencies in hematology, and understand how these competencies could be learned in hematology residency training.

Methods: Semi-structured interviews were conducted with practicing hematologists in Ontario, Canada to elicit key health advocacy competencies for hematologists and learn how these are acquired. Participants were selected using a purposeful, maximal variation sampling strategy. Interviews were recorded in their entirety and transcribed by hand. Data were deidentified after collection and a computer software (NVivo) was used to create codes through an iterative approach. The codes were analyzed using the thematic analysis technique outline by Braun and Clarke (Braun & Clarke, 2006). A deductive approach was employed, incorporating the CanMEDs framework and previously described conceptual frameworks pertaining to health advocacy.

Results: 8 hematologists (5 academic-based, 3 community-based; 4 malignant hematologists and 4 non-malignant hematologists) were included. Hematologists engage in advocacy activities at the clinical, paraclinical, and supraclinical levels and conduct advocacy work most commonly through a directed agency strategy. Drug access was the most prominent advocacy challenge encountered by hematologists. Health disparities that were identified included the rural/remote divide and socioeconomic status. Health advocacy competencies employed by hematologists closely resembled those used by other physicians, with some difference on emphasis. Skills that hematologists found were important to advocacy training were leveraging interprofessional connections, using research as advocacy, and acquiring health systems knowledge. Early exposure to advocacy in training, effective mentorship, and learning from practical examples and experience were viewed as the most effective ways to learn health advocacy skills.

Conclusion: This study identified the breadth of advocacy activities conducted by hematologists and identified numerous competencies that are important to being an effective health advocate. Health advocacy education in hematology training programs should start early, be practical and engaging, be integrated longitudinally into existing teaching and learning activities, and harness the power of mentorship relationships. This work is the first step in addressing the informational gap required to design a novel health advocacy curriculum for hematology residents.

Disclosures: Tseng: Fresenius Kabi: Other: Advisory board; Pfizer: Other: Advisory board; Inari: Other: Advisory board. Scott: Amgen: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; Recordati Rare diseases: Other: travel support; Alnylam Pharmaceuticals: Other: travel support .

*signifies non-member of ASH